Citadel Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$290M Buy
4,782,000
+784,400
+20% +$45.7M 0.05% 318
2025
Q4
$216M Buy
3,997,600
+163,300
+4% +$7.86M 0.03% 451
2025
Q3
$173M Buy
3,834,300
+906,500
+31% +$42.3M 0.03% 541
2025
Q2
$136M Sell
2,927,800
-640,400
-18% -$31.4M 0.02% 572
2025
Q1
$218M Sell
3,568,200
-354,300
-9% -$20.7M 0.04% 345
2024
Q4
$222M Sell
3,922,500
-2,996,000
-43% -$167M 0.04% 373
2024
Q3
$358M Sell
6,918,500
-1,939,900
-22% -$91M 0.07% 201
2024
Q2
$368M Buy
8,858,400
+3,882,700
+78% +$174M 0.07% 184
2024
Q1
$270M Buy
4,975,700
+2,100,700
+73% +$107M 0.05% 276
2023
Q4
$148M Buy
2,875,000
+122,400
+4% +$6.43M 0.03% 481
2023
Q3
$160M Sell
2,752,600
-143,100
-5% -$8.77M 0.03% 396
2023
Q2
$185M Buy
2,895,700
+113,500
+4% +$7.61M 0.04% 351
2023
Q1
$193M Sell
2,782,200
-271,900
-9% -$19.2M 0.04% 335
2022
Q4
$220M Sell
3,054,100
-733,000
-19% -$55.3M 0.05% 310
2022
Q3
$269M Buy
3,787,100
+512,900
+16% +$37.2M 0.06% 210
2022
Q2
$252M Sell
3,274,200
-58,900
-2% -$4.49M 0.06% 220
2022
Q1
$243M Sell
3,333,100
-230,900
-6% -$15.5M 0.05% 274
2021
Q4
$222M Buy
3,564,000
+939,700
+36% +$55.1M 0.05% 309
2021
Q3
$155M Buy
2,624,300
+881,900
+51% +$58.1M 0.03% 444
2021
Q2
$116M Buy
1,742,400
+607,900
+54% +$39.6M 0.03% 584
2021
Q1
$71.6M Sell
1,134,500
-844,300
-43% -$52.5M 0.02% 777
2020
Q4
$123M Buy
1,978,800
+1,105,900
+127% +$68M 0.03% 440
2020
Q3
$52.6M Sell
872,900
-130,200
-13% -$7.84M 0.01% 827
2020
Q2
$59M Sell
1,003,100
-1,300,900
-56% -$77.8M 0.02% 698
2020
Q1
$128M Buy
2,304,000
+1,562,600
+211% +$95.5M 0.06% 249
2019
Q4
$47.6M Sell
741,400
-1,109,200
-60% -$63.5M 0.02% 798
2019
Q3
$93.8M Sell
1,850,600
-44,500
-2% -$2.09M 0.04% 430
2019
Q2
$85.9M Sell
1,895,100
-1,295,400
-41% -$60.3M 0.04% 461
2019
Q1
$152M Buy
3,190,500
+1,784,700
+127% +$88.9M 0.08% 216
2018
Q4
$73.1M Sell
1,405,800
-264,800
-16% -$14.2M 0.04% 451
2018
Q3
$104M Buy
1,670,600
+269,900
+19% +$16M 0.05% 401
2018
Q2
$77.5M Buy
1,400,700
+181,800
+15% +$9.82M 0.04% 472
2018
Q1
$77.1M Buy
1,218,900
+482,900
+66% +$31.1M 0.04% 410
2017
Q4
$45.1M Sell
736,000
-165,300
-18% -$10.3M 0.03% 667
2017
Q3
$57.4M Sell
901,300
-152,400
-14% -$8.9M 0.04% 479
2017
Q2
$58.7M Sell
1,053,700
-89,300
-8% -$4.86M 0.05% 425
2017
Q1
$62.2M Buy
1,143,000
+272,200
+31% +$14.9M 0.06% 348
2016
Q4
$50.9M Sell
870,800
-638,400
-42% -$34.9M 0.05% 380
2016
Q3
$81.4M Buy
1,509,200
+919,900
+156% +$59.1M 0.08% 215
2016
Q2
$43.3M Buy
589,300
+60,100
+11% +$4.25M 0.05% 395
2016
Q1
$33.8M Buy
529,200
+225,600
+74% +$14.2M 0.04% 454
2015
Q4
$20.9M Sell
303,600
-98,200
-24% -$6.49M 0.02% 819
2015
Q3
$23.8M Buy
401,800
+195,000
+94% +$12.4M 0.02% 794
2015
Q2
$13.8M Buy
206,800
+16,000
+8% +$1.05M 0.01% 1255
2015
Q1
$12.3M Buy
190,800
+59,200
+45% +$3.71M 0.01% 1287
2014
Q4
$7.77M Sell
131,600
-62,600
-32% -$3.53M 0.01% 1598
2014
Q3
$9.94M Buy
194,200
+99,400
+105% +$4.97M 0.01% 1366
2014
Q2
$4.6M Sell
94,800
-79,900
-46% -$3.94M 0.01% 1901
2014
Q1
$9.08M Sell
174,700
-160,400
-48% -$8.54M 0.01% 1335
2013
Q4
$17.8M Sell
335,100
-365,000
-52% -$18.6M 0.02% 868
2013
Q3
$32.4M Buy
700,100
+312,200
+80% +$13.7M 0.05% 494
2013
Q2
$17.3M Buy
+387,900
New +$16.8M 0.03% 735

Other funds holding BMY

Citadel Advisors's BMY Position: Q1 2026 in Review

Citadel Advisors increased its Bristol-Myers Squibb (BMY) stake by 46% in Q1 2026, buying an estimated $27.5M and bringing the position to 1,494,234 shares worth $90.6M. The position accounts for 0.01% of the portfolio, ranked #884.

Citadel Advisors first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $456M in Q2 2024. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Citadel Advisors held 1,494,234 shares of Bristol-Myers Squibb worth $90.6M as of Q1 2026.
  • Citadel Advisors bought 471,773 Bristol-Myers Squibb shares in Q1 2026, an estimated $27.5M.
  • Bristol-Myers Squibb made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #884 holding.
  • Citadel Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Bristol-Myers Squibb position peaked at $456M in Q2 2024.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.